CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide
Abstract Number : 5569
Abstract Type : Poster Session
Indication : Metastatic Castration Resistant Prostate Cancer
Intervention : Cabazitaxel versus abiraterone or enzalutamide
Company : Sanofi
Technology : Chemotherapy
In the CARD study (N = 255), median OS was longer with cabazitaxel vs. abiraterone/enzalutamide (13.6 vs 11.0 months; HR 0.64, 95% CI 0.46–0.89; p = 0.008). OS was numerically improved for cabazitaxel vs. abiraterone/enzalutamide when assessed from the time of diagnosis of metastatic disease or mCRPC, or from start of 1st or 2nd LET (Table). In the multivariate analysis, low hemoglobin, high baseline neutrophil to lymphocyte ratio, and high PSA values at baseline were associated with worse OS. In presence of these factors, the OS benefit observed with cabazitaxel versus abiraterone/enzalutamide remained significant (HR 0.63, 95% CI 0.42–0.94, p = 0.022).
Cabazitaxel numerically improved OS vs. abiraterone/enzalutamide in patients with mCRPC previously treated with docetaxel and the alternative ART (abiraterone/enzalutamide), whatever the time point considered. The robustness of this OS benefit was confirmed by stratified multivariate analysis.
Cabazitaxel showed a statistically significant improvement in overall survival compared to abiraterone or enzalutamide in patients previously treated with docetaxel and the alternative ART.
Refer to Metastatic Castration Resistant Prostate Cancer Market report for detailed Insights.